Table 2.

T2D in relation to incidence of invasive breast cancer

Person yearsBreast cancer casesAge-adjusted HR (95% CI)MV HRa (95% CI)
All breast cancer
 No diabetes812,9451,688ReferenceReference
 T2D54,8751631.12 (0.95–1.32)1.18 (1.00–1.40)
Time since T2D diagnosis
 <5 years6,649181.03 (0.65–1.64)1.07 (0.67–1.70)
 ≥5 years48,2251451.13 (0.95–1.35)1.20 (1.00–1.43)
ER+ breast cancer
 No diabetes812,034841ReferenceReference
 T2D54,780730.98 (0.77–1.25)1.02 (0.80–1.31)
Time since T2D diagnosis
 <5 years6,63980.86 (0.43–1.72)0.88 (0.44–1.77)
 ≥5 years48,141651.00 (0.77–1.29)1.05 (0.80–1.36)
ER− breast cancer
 No diabetes811,623426ReferenceReference
 T2D54,759421.33 (0.96–1.85)1.43 (1.03–2.00)
Time since T2D diagnosis
 <5 years6,63751.17 (0.48–2.84)1.23 (0.51–2.98)
 ≥5 years48,122371.36 (0.96–1.92)1.46 (1.03–2.08)
  • Abbreviation: MV, multivariable.

  • aAdjusted for age, BMI, BMI at age 18, parity, age at first birth, age at menarche, duration of oral contraceptive use, duration of menopausal hormone use, and first degree family history of breast cancer.